Lataa...
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Hea...
Tallennettuna:
| Julkaisussa: | Rheumatol Ther |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Healthcare
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5696295/ https://ncbi.nlm.nih.gov/pubmed/28956301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-017-0083-1 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|